GTC
IONS icon

Ghost Tree Capital’s Ionis Pharmaceuticals IONS Stock Holding History

Ghost Tree Capital’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-50,000
Closed -$3.09M – 73
2014
Q4 		$3.09M Buy
+50,000
New +$2.47M 1.48% 31

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ghost Tree Capital's IONS Position: Q4 2016 in Review

Ghost Tree Capital sold out of Ionis Pharmaceuticals (IONS) in Q4 2016, closing a stake of 25,000 shares — an estimated $916K sold.

Ghost Tree Capital first reported a position in IONS in Q3 2016 and held it in 1 quarter. The position peaked at $916K in Q3 2016. 308 funds tracked by Wall St. Rank hold IONS as of Q4 2016.

  • Ghost Tree Capital reported no remaining Ionis Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Ghost Tree Capital sold 25,000 Ionis Pharmaceuticals shares in Q4 2016, an estimated $916K.
  • Ghost Tree Capital first reported a position in Ionis Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Ghost Tree Capital's Ionis Pharmaceuticals position peaked at $916K in Q3 2016.
  • 308 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2016.

Based on Ghost Tree Capital's 13F filing for Q4 2016, filed 14 Feb 2017.